Online inquiry

IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ665MR)

This product GTTS-WQ665MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Cancers, brain, metastatic research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ665MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12551MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NV-01
GTTS-WQ7030MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Fab C225
GTTS-WQ6365MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ12456MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ1613MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ15897MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ10248MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ3900MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW